Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B
- PMID: 21036792
- DOI: 10.1136/gut.2010.223206
Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B
Abstract
Objective: To determine the efficacy of tenofovir disoproxil fumarate (TDF) in adults with chronic hepatitis B virus (HBV) infection who had previously failed lamivudine (LAM) and had significant viral replication (HBV DNA >10⁵ copies/ml if HBeAg positive, > 10⁴ copies/ml if HBeAg negative) despite at least 24 weeks of treatment with adefovir dipivoxil (ADV).
Design: A prospective open-label study of TDF 300 mg daily. Patients receiving combination ADV/LAM prior to baseline were switched to TDF/LAM.
Setting: Multiple tertiary referral centres.
Methods: Sixty patients were enrolled. The median age was 48.5 years (range 21e80), 46 (77%) were male and 40 (67%) were HBeAg positive. Thirty-eight patients (63%) were switched from ADV to TDF, the remainder from ADV/LAM to TDF/LAM. At baseline, substitutions conferring resistance to LAM or ADV were present in 20 patients (33%) and 17 patients (28%), respectively. The median baseline viral load was 5.33 log₁₀ IU/ml (range 2.81-8.04). Patients initially treated with TDF monotherapy with persistent viral replication at or after 24 weeks were switched to TDF/LAM. The main outcome measures were change in HBV viral load from baseline and percentage of patients achieving an undetectable viral load (<15 IU/ml).
Results: Results are reported at 96 weeks of treatment. One patient discontinued TDF at 10 days due to rash. The time-weighted change in viral load from baseline to week 12 was -2.19 log10 IU/ml overall. The median change in HBV DNA from baseline to weeks 12, 24, 48 and 96 was -2.86, -3.23, -3.75 and -4.03 log₁₀ IU/ml, respectively. At 48 and 96 weeks, 27/59 (46%) and 38/59 (64%) patients achieved a HBV DNA <15 IU/ml. The response was independent of baseline LAM therapy or mutations conferring ADV resistance.
Conclusions: In heavily pretreated patients with a high rate of genotypic resistance, TDF retains significant activity against HBV although this appears diminished in comparison with studies of naïve patients.
Comment in
-
Tenofovir salvage for nucleoside experienced patients: muddy waters?Gut. 2011 Feb;60(2):148-50. doi: 10.1136/gut.2010.229062. Gut. 2011. PMID: 21205876 No abstract available.
Similar articles
-
Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.World J Gastroenterol. 2015 Mar 7;21(9):2746-53. doi: 10.3748/wjg.v21.i9.2746. World J Gastroenterol. 2015. PMID: 25759545 Free PMC article.
-
Comparative meta-analysis of adefovir dipivoxil monotherapy and combination therapy of adefovir dipivoxil and lamivudine for lamivudine-resistant chronic hepatitis B.Int J Infect Dis. 2012 Mar;16(3):e152-8. doi: 10.1016/j.ijid.2011.11.006. Epub 2012 Jan 4. Int J Infect Dis. 2012. PMID: 22226087 Review.
-
Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection.Gastroenterology. 2010 Oct;139(4):1207-17. doi: 10.1053/j.gastro.2010.06.053. Epub 2010 Jun 20. Gastroenterology. 2010. PMID: 20600025 Clinical Trial.
-
Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.Clin Ther. 2008 Feb;30(2):317-23. doi: 10.1016/j.clinthera.2008.02.012. Clin Ther. 2008. PMID: 18343270
-
Treatment of patients with chronic hepatitis B with adefovir dipivoxil.Semin Liver Dis. 2004;24 Suppl 1:37-44. doi: 10.1055/s-2004-828677. Semin Liver Dis. 2004. PMID: 15192800 Review.
Cited by
-
Switching from Tenofovir-Based Combination Therapy to Tenofovir Monotherapy in Multidrug-Experienced Chronic Hepatitis B Patients: a 5-Year Experience at Two Centers.Antimicrob Agents Chemother. 2022 Aug 16;66(8):e0027522. doi: 10.1128/aac.00275-22. Epub 2022 Jul 13. Antimicrob Agents Chemother. 2022. PMID: 35867571 Free PMC article.
-
Tenofovir disoproxil fumarate for multiple nucleos(t)ide analogues treatment failure hepatitis B: Is monotherapy enough?J Gastroenterol Hepatol. 2022 Mar;37(3):471-479. doi: 10.1111/jgh.15757. Epub 2022 Jan 6. J Gastroenterol Hepatol. 2022. PMID: 34894002 Free PMC article.
-
Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response.Clin Mol Hepatol. 2020 Jul;26(3):352-363. doi: 10.3350/cmh.2019.0044n. Epub 2020 May 28. Clin Mol Hepatol. 2020. PMID: 32460460 Free PMC article. Clinical Trial.
-
Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review.J Gastroenterol. 2020 May;55(5):496-514. doi: 10.1007/s00535-020-01680-0. Epub 2020 Mar 17. J Gastroenterol. 2020. PMID: 32185517 Free PMC article.
-
Efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B virus infection: A 2-year prospective study.Medicine (Baltimore). 2019 Oct;98(42):e17590. doi: 10.1097/MD.0000000000017590. Medicine (Baltimore). 2019. PMID: 31626130 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical